Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xanthus Pharmaceuticals has presented positive results from three collaborative in vitro studies into the mechanism of action of Xanafide, a topoisomerase II inhibitor that is currently in a pivotal Phase III trial for the treatment of secondary acute myeloid leukemia.
Subscribe to our email newsletter
Data from these studies showed that Xanafide (amonafide malate) triggered a similar level of apoptosis but with less DNA damage. While Xanafide targeted many of the same genes as daunorubicin, it was less susceptible to resistance mechanisms. Xanafide was also effluxed substantially less than daunorubicin when tested on cells from patients with acute myeloid leukemia (AML). These in vitro studies demonstrated how Xanafide acts differently from classical topoisomerase inhibitors such as daunorubicin.
Richard Dean, CEO of Xanthus, said: “These studies extend our prior findings on Xanafide’s mechanism of action and continue to strengthen the supporting data for the use of Xanafide as a new treatment for AML and other blood cancers. The unique mechanism and resistance profile demonstrated in these and other in vitro studies support our belief that Xanafide may offer an important new treatment option for patients with secondary AML.”